Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
To evaluate the persistence of bactericidal antibodies in adolescents and adults who received
 one dose of Menactra® vaccine approximately four to eight years earlier
Subjects who received one dose of Menactra® or Menomune® in study MTA04, MTA12, MTA19
 (NCT00777790), or MTA21 (NCT00777257) will be eligible for enrollment in trial this study.
 All eligible subjects will provide a blood sample at Visit 1, after which their participation
 in the study will be terminated. An age-matched meningococcal-vaccine naïve control group
 will be recruited to provide a blood sample for baseline antibody level evaluation.

 No vaccine will be administered in this study.
Inclusion Criteria :

 -  For subjects aged ≥ 18 years: Informed consent form signed and dated by the subject

 -  For subjects aged < 18 years: Informed consent form signed and dated by the subject
 and the subject's parent/legal guardian

 -  Subject (and parent/legal guardian if subject is < 18 years of age) able to attend the
 scheduled visit and comply with all trial procedures

 -  For Group 1: Previously received only one dose of meningococcal vaccine (Menactra®,
 received in Study MTA04, MTA12, MTA19, or MTA21)

 -  For Group 2: Previously received only one dose of meningococcal vaccine (Menomune®,
 received in Study MTA04)

 -  For Group 3: Aged 14 through 27 years and never received any meningococcal vaccine

 Exclusion Criteria :

 -  Participation in another clinical trial investigating a vaccine, drug, medical device,
 or a medical procedure in the 4 weeks preceding inclusion

 -  Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy
 such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months,
 or long-term systemic corticosteroids therapy > 2 weeks

 -  Chronic illness at a stage that could interfere with trial conduct or completion, in
 the opinion of the investigator

 -  Current alcohol abuse or drug addiction that may interfere with the subject's ability
 to comply with trial procedures

 -  Receipt of blood or blood-derived products in the past 3 months that might interfere
 with the assessment of immune responses

 -  Known Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C seropositivity

 -  History of invasive meningococcal disease (confirmed either clinically, serologically,
 or microbiologically)

 -  For Groups 1 and 2: Previous vaccination (including booster) against meningococcal
 disease, with the exception of the Menactra® or Menomune® vaccination received in
 trial MTA04, MTA12, MTA19, or MTA21

 -  Subjects deprived of freedom by an administrative or court order, or in an emergency
 setting, or hospitalized without his/her consent

 -  Received oral or injected antibiotic therapy within the 72 hours prior to the blood
 draw (temporary criteria)